HIGHLIGHTS
- who: Ankur Sheel from the Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA have published the Article: Reversible cardiomyopathy in a patient with chronic myelomonocytic leukemia treated with decitabine/cedazuridine: a case report, in the Journal: (JOURNAL)
- what: This case is the first to demonstrate an example of cardiotoxicity in patient with CMML after completion of 5 cycles of decitabine/cedazuridine therapy in a patient without pre-existing cardiovascular disease.
- future: Future studies are required to associate TET2 mutational burden with decitabine-cedauziridne toxicity and efficacy as . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.